menu
    • menu
    [{"orgOrder":0,"company":"OncoTEX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oxaliplatin Pt(IV) Prodrug","moa":"Mutant p53","graph1":"Oncology","graph2":"Undisclosed","graph3":"OncoTEX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OncoTEX \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"OncoTEX \/ Not Applicable"},{"orgOrder":0,"company":"OncoTEX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoTEX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoTEX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoTEX \/ Inapplicable"},{"orgOrder":0,"company":"OncoTEX","sponsor":"Sterling Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Oxaliplatin","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoTEX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoTEX \/ OncoTEX","highestDevelopmentStatusID":"4","companyTruncated":"OncoTEX \/ OncoTEX"}]

    Find Clinical Drug Pipeline Developments & Deals by OncoTEX

    Menu

    OncoTEX

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OncoTEX

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            OncoTEX

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxaliplatin,Texaphryn

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OncoTEX Receives Notice of Allowance for Patent in Korea Regarding Ovarian Cancer-Fighting Drug OxaliTEX

                            Details : OxaliTEX, is the first clinical candidate developed from the TEX Core platform for the treatment of platinum-resistant ovarian cancer, has received a notice of allowance for patent in Korea adds further global protection.

                            Product Name : OxaliTEX

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 30, 2022

                            Lead Product(s) : Oxaliplatin,Texaphryn

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OncoTEX

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            OncoTEX

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxaliplatin Pt(IV) Prodrug,Texaphyrin

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoTEX Issued New U.S. Patent for Ovarian Cancer-Fighting Drug OxaliTEX

                            Details : OxaliTEX is first clinical candidate developed from TEX Core platform for treatment of ovarian cancer, also overcomes platinum resistance, and is tumor localizing, well-tolerated, and MRI-detectable to allow clinicians and patients to easily monitor tumo...

                            Product Name : OxaliTEX

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 14, 2022

                            Lead Product(s) : Oxaliplatin Pt(IV) Prodrug,Texaphyrin

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            OncoTEX

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            OncoTEX

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxaliplatin,Texaphryn

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Sterling Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            OncoTEX and Sterling Pharma Solutions Sign Clinical Manufacturing Agreement for the Development of Novel Treat...

                            Details : OxaliTEX, a conjugation of oxaliplatin and texaphryn, which localizes to solid tumors including ovarian, lung and colorectal cancers. Under the terms of the agreement, Sterling will produce clinical material in its cGMP facility in Germantown, Wisconsin.

                            Product Name : OxaliTEX

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            May 13, 2021

                            Lead Product(s) : Oxaliplatin,Texaphryn

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Sterling Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth